Mitral Valve Disease Market Outlook 2024-2033

Spread the love

Market Size –
The mitral valve disease market size has grown strongly in recent years. It will grow from $2.75 billion in 2023 to $3 billion in 2024 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to patient education initiatives, adequate reimbursement policies and insurance coverage, growing healthcare expenditure, rising awareness and screening efforts, and expanding market presence.

The mitral valve disease market size is expected to see strong growth in the next few years. It will grow to $4.32 billion in 2028 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to growing prevalence of mitral valve disease, increasing adoption for minimally invasive techniques, soaring innovations in heart valve surgery, rise venture capital investments, and rising interest of manufacturers. Major trends in the forecast period include technological advancements, advancements in transcatheter technologies, and increasing technological advancements in surgical procedures.

Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/mitral-valve-disease-global-market-report

Scope Of Mitral Valve Disease Market
The Business Research Company’s reports encompass a wide range of information, including:

1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.

2. Drivers: Examination of the key factors propelling market growth.

3. Trends: Identification of emerging trends and patterns shaping the market landscape.

4. Key Segments: Breakdown of the market into its primary segments and their respective performance.

5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.

6. Macro Economic Factors: Assessment of broader economic elements impacting the market.

Mitral Valve Disease Market Overview

Market Drivers –
The increasing prevalence of vascular heart diseases is expected to propel the growth of mitral valve disease market going forward. Vascular heart diseases encompass a group of conditions affecting the blood vessels supplying the heart or within the heart itself. A complex interplay of lifestyle choices, demographic changes, medical conditions, environmental factors, and genetic variables drives the increasing cases of vascular heart diseases. Vascular heart diseases, such as ischemic heart disease and hypertension, can indirectly cause mitral valve disease by compromising the heart’s structure and function, leading to conditions that affect the mitral valve. For instance, in December 2023, according to data from the Australian Bureau of Statistics 2020-21 National Health Survey conducted by the Australian Institute of Health and Welfare, an Australia-based government agency, an estimated 571,000 adults aged 18 and over in Australia were living with coronary heart disease (CHD), comprising 2.9% of the adult population. Moreover, the prevalence of CHD rises significantly with age, impacting approximately 11% of adults aged 75 and above. Therefore, the increasing prevalence of vascular heart diseases is driving the mitral valve disease market.

Market Trends –
Major companies operating in the mitral valve disease market are developing stented tissue valves to address the growing demand for minimally invasive treatment options. Stented tissue valves are designed to provide durable and reliable performance, offering patients an alternative to traditional surgical interventions. For instance, in September 2021, Abbott Laboratories, a US-based medical devices and healthcare company, received approval from the FDA for Epic Plus and Epic Plus Supra stented tissue valves to treat individuals with aortic or mitral valve disease. These advanced devices are based on Abbott’s trusted Epic surgical valve platform and anti-calification technology. Additionally, both valves feature a FlexFit polymer stent that can withstand approximately 8 atm pressure during balloon valvuloplasty procedures, a unique pericardial shield to prevent abrasion risk, and a flexible cuff to mitigate paravalvular leak (PVL) and fit patient anatomy.

The mitral valve disease market covered in this report is segmented –

1) By Treatment Type: Mitral Valve Repair, Mitral Valve Replacement, Cardiac Resynchronization Therapy, Mitral Valve Therapeutics
2) By Indication: Mitral Valve Stenosis, Mitral Valve Prolapse, Mitral Valve Regurgitation
3) By End-User: Hospitals, Ambulatory Surgical Centers, Other End-Users

Get an inside scoop of the mitral valve disease market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=16480&type=smp

Regional Insights –
Europe was the largest region in the mitral valve disease market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mitral valve disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Key Companies –

Major companies operating in the mitral valve disease market are Pfizer Inc., Bayer AG, Abbott Laboratories, Novartis AG, Medtronic plc, Boston Scientific Corporation, Edwards Lifesciences, ShockWave Medical Inc., Artivion Inc., TTK Health Care Limited, Braile Biomedica, JenaValve Technology Inc., 4C Medical technologies, Labcor Laboratorios Ltda, CryoLife Inc., Valcare Medical, Affluent Medical, Colibri Heart Valve LLC, Coramaze Technologies, Corcym UK Limited, HighLife Medical, Micro International Devices Inc., Neovasc Inc., Mitralign Inc., Transcatheter Technologies GmbH

Table of Contents
1. Executive Summary
2. Mitral Valve Disease Market Characteristics
3. Mitral Valve Disease Market Trends And Strategies
4. Mitral Valve Disease Market – Macro Economic Scenario
5. Global Mitral Valve Disease Market Size and Growth
.
.
.
31. Mitral Valve Disease Market Other Major And Innovative Companies
32. Global Mitral Valve Disease Market Competitive Benchmarking
33. Global Mitral Valve Disease Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Mitral Valve Disease Market
35. Mitral Valve Disease Market Future Outlook and Potential Analysis
36.Appendix

Email: [email protected]

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-modelMarket Size –
The mitral valve disease market size has grown strongly in recent years. It will grow from $2.75 billion in 2023 to $3 billion in 2024 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to patient education initiatives, adequate reimbursement policies and insurance coverage, growing healthcare expenditure, rising awareness and screening efforts, and expanding market presence.